Back to results
US 2019/0292541 A1Published application
Method for efficient exon (44) skipping in duchenne muscular dystrophy and associated means
AssigneesBioMarin Technologies B.V., Academisch Ziekenhuis Leiden
InventorsGerard Johannes Platenburg, Josephus Johannes De Kimpe, Judith Christina Theodora Van Deutekom, Garrit-Jan Boudewijn Van Ommen, Annemieke Aartsma-Rus
Life of this patent
Estimating the term…
Abstract
The invention relates to a nucleic acid molecule that binds and/or is complementary to the nucleotide molecule having sequence 5′GUGGCUAACAGAAGCU (SEQ ID NO 1) and to its use in a method for inducing skipping of exon 44 of the DMD gene in a DMD patient.
Claims12
A single stranded antisense oligonucleotide 20 to 25 nucleotides in length that comprises a base sequence that binds and/or is complementary to SEQ ID NO:
- 3, wherein the antisense oligonucleotide induces skipping of exon 44 of human dystrophin pre-mRNA, and comprises a modification.
Dependencies are inferred from the claim text.